ABSTRACT
Introducción: Los tumores luminales presentan diferencias moleculares y distinto comportamiento. El antígeno ki67 (ki67) es uno de los factores que sirve para diferenciar entre luminal A y B. Las plataformas genómicas pueden identificar qué pacientes se benefician con quimioterapia. Objetivo: Establecer si existe asociación entre ki67 y Score de Oncotype Dx o score de recurrencia (SR). Evaluar la influencia del ki67 y el SR en la decisión terapéutica, evaluar la asociación entre riesgo clínico y SR, entre invasión linfovascular (ILV) y SR y entre axila positiva (hasta 1 ganglio) y SR. Material y método: Estudio retrospectivo, observacional, descriptivo. Se incluyeron 68 pacientes con tumores luminales Her2Neu negativos, T1-T2, axila negativa o positiva hasta 1 ganglio las cuales realizaron Oncotype DX entre 2009 y 2020 en el Hospital Alemán. Se clasificaron en SR menor o igual a 25 y mayor a 25 en base al estudio TAILORX donde se demostró que globalmente no hay beneficio con quimioterapia entre 0-25. Resultados: Se observó asociación entre ki67 y SR en 44 (64,7%) pacientes y fue mayor entre ki67 bajo y SR menor o igual a 25 (77,3%). El tratamiento se basó en el SR. Se observó asociación entre riesgo clínico y SR en 43 (63,2%) pacientes y fue mayor entre bajo riesgo clínico y SR menor o igual a 25 (87,5%). En un 88,8% no existió asociación entre ILV y SR, como así tampoco, entre axila positiva hasta 1 ganglio y SR en un 85,7%. Conclusiones: Es menester ofrecer a toda paciente con un tumor luminal una plataforma genómica ya que tanto el ki67 como otros factores clínicopatológicos por sí solos no demostraron ser superiores ni suficientes.
Introduction: Luminal tumors show molecular differences and different behavior. The antigen ki67 (ki67) is one of the factors that differentiate between luminal A and B. Genomic platforms can identify which patients will benefit from chemotherapy. Objective: To establish if there is an association between ki67 and Oncotype Dx Score or recurrence score (RS). To assess the influence of ki67 and RS on the therapeutic decision, to evaluate the association between clinical risk and RS, between lymphovascular invasion (LVI) and RS, and between positive armpit (up to 1 node) and RS. Material and method: Retrospective, observational, descriptive study. We included 68 patients with negative Her2Neu luminal tumors, T1-T2, negative or positive axillary up to 1 node, who performed Oncotype DX between 2009 and 2020 at Hospital Alemán. They were classified into RS less than or equal to 25 and greater than 25 based on the TAILORX study, where it was shown that overall there is no benefit from chemothe- rapy between 0-25. Results: An association was observed between ki67 and RS in 44 (64.7%) patients and it was greater between low ki67 and RS less than or equal to 25 (77.3%). The treatment was based on RS. An association between clinical risk and RS was observed in 43 (63.2%) patients, and it was greater between low clinical risk and RS less than or equal to 25 (87.5%). In 88.8% there was no association between LVI and RS, as well as between positive axillary up to 1 node and RS in 85.7%. Conclusions: It is necessary to offer every patient with a luminal tumor a genomic platform since both ki67 and other clinicopathological factors alone did not prove to be superior or sufficient.
Subject(s)
Female , Breast Neoplasms , Therapeutics , Ki-67 Antigen , Drug Therapy , AntigensABSTRACT
Objetivos El objetivo primario del presente estudio es analizar cómo la utilización del ensayo Oncotype Dx modifica y condiciona la elección del tratamiento adyuvante. En segundo lugar, nos propusimos evaluar la evolución de aquellas pacientes con score de recurrencia menor a 10, las cuales han sido clasificadas en el ensayo clínico TailorX como pacientes de bajo riesgo pasibles de ser tratadas solo con terapia hormonal adyuvante Por último, buscamos evaluar si existe correlación entre el valor de Ki 67, la invasión linfovascular (ILV) y el score del Oncotype Dx. Material y método Analizamos retrospectivamente 62 pacientes con cáncer de mama con receptores hormonales positivos, her2 Neu negativo y ganglios negativos, a las cuales se les solicitó el score de recurrencia Oncotype Dx, y comparamos con las indicaciones de terapia adyuvante surgidas previamente de factores de riesgo clínicos y anátomo-patológicos. Resultados Treinta pacientes (48,4%) presentaron score de bajo riesgo, 25 (40,3%) score de riesgo intermedio y las 7 restantes (11,3%) score de alto riesgo de recurrencia. Analizando el cambio de conducta, una vez obtenido el resultado del Oncotype Dx, encontramos un cambio de decisión en 16 pacientes (26%). Según la indicación de los factores de riesgo clínicos y anátomo-patológicos, de las 62 pacientes incluidas en este estudio, se había indicado adyuvancia con quimioterapia y hormonoterapia a 26 pacientes y hormonoterapia solamente a las 36 pacientes restantes. Posterior a la realización del Oncotype Dx, de las 26 pacientes a las cuales se les había indicado quimioterapia, en 12 se modificó el tratamiento a adyuvancia hormonal solamente (46,15% de reducción de la indicación en este grupo). Por otra parte, en aquellas 36 pacientes respecto de las cuales nuestra indicación previa había sido solamente adyuvancia hormonal, el resultado del Oncotype Dx determinó la realización de quimioterapia en 4 (11,1%). Cotejando la correlación entre Oncotype Dx y factores anátomo-patológicos, encontramos como dato interesante que todas aquellas pacientes con score de alto riesgo presentaban Ki 67 elevado, pero no a la inversa, mientras que no hallamos relación entre invasión linfovascular (ilv) presente y Oncotype Dx elevado. Conclusiones Consideramos que la utilización de plataformas genómicas como el Oncotype Dx es un elemento útil a la hora de tomar decisiones sobre el tratamiento adyuvante del carcinoma de mama Luminal con ganglios negativos, donde la indicación de la quimioterapia adyuvante debe ser cuidadosamente evaluada.
Objectives The primary objective is to analyze how the use of Oncotype Dx modifies and conditions the choice of adjuvant treatment. Second, to evaluate the evolution of those patients with score of recurrence <10 of low risk in TailorX Clinical Trial, treatable with hormonal adjuvancy only. Finally, compare correlation between lymphovascular invasion (ilv), Ki 67 and Oncotype High Dx. Materials and method We retrospectively analyzed 62 breast cancer patients with hormone receptor positive, hers Neu negative and negative lymph nodes, who were asked for the Oncotype Dx recurrence score and compared with the indications for adjuvant therapy that had previously arisen from clinical and anatomic risk factors pathological. Results Thirty patients (48.4%) presented a low risk score, 25 patients (40.3%) intermediate risk and the remaining 7 patients (11.3%), a high risk score for recurrence. Once the Oncotype Dx result was obtained, we found a decision change in 16 patients (26%). According to the indication of the clinical and anatomopathological risk factors, of the 62 patients included in this study, adjuvancy had been indicated with chemotherapy and hormone therapy to 26 patients and only hormone therapy to the remaining 36 patients. After the Oncotype Dx, of the 26 patients to whom chemotherapy had been indicated, in 12 of them the treatment was modified to hormonal adjuvancy only (46.15% reduction of the indication in this group). On the other hand, in those 36 patients that our previous indication had been only hormonal adjuvancy, the result of the Oncotype Dx determined the accomplishment of chemotherapy in 4 of them (11.1%). Comparing the correlation between Oncotype Dx and anatomopathological factors, we found that all those patients with a high risk score had elevated Ki 67, but not inversely, whereas we did not find a relation between present lymphovascular invasion (ilv) and Oncotype High Dx. Conclusions We believe that the use of genomic platforms such as Oncotype Dx is a useful element when making decisions about the adjuvant treatment of Luminal breast cancer with negative ganglia, where the indication of adjuvant chemotherapy should be carefully evaluated.
Subject(s)
Humans , Female , Breast Neoplasms , Chemotherapy, AdjuvantABSTRACT
INTRODUCTION: The instillation of surfactant into the airways of patients with respiratory distress syndrome (RDS), especially in the neonatal period, is a proven therapy. The preventive therapy of RDS through intra-amniotic injection of surfactant has been reported recently. It has not been conclusively shown, however, that the surfactant administered in this way actually reaches the fetal pulmonary airways. OBJECTIVE: To study the distribution in fetal organs of a natural surfactant labeled with technetium-99m and injected through amniocentesis into the amniotic sac of guinea pigs in the last third of pregnancy. METHODS: After stimulating fetal respiratory movements with aminophylline 0.3 ml of an aqueous suspension containing 0.75 mg of phospholipids of a natural bovine surfactant labeled with technetium-99m, together with 0.1 ml of the biological dye carmine indigo, were injected into the amniotic sac. One hour later fetuses were delivered by cesarean section. In those that were dye-stained, dosimetric and gammagraphic tests were applied to trachea, lungs, esophagus, stomach, heart, liver, kidneys and placenta. RESULTS: Significant radio isotopic activity was found in both lungs of six treated fetuses, with a dose capture of between 1.0% and 5.3% of total dose. The level of activity in the stomachs was similar to that in the lungs (0.9% to 3.0% dose capture), whereas activity in other organs was negligible except in two placentae. No radio isotopic activity was found in non-injected control fetuses. CONCLUSIONS: In the present animal model natural surfactant injected intra-amniotically is aspirated into the lungs within one hour.
Subject(s)
Lung/drug effects , Pulmonary Surfactants/pharmacology , Respiratory Distress Syndrome, Newborn/prevention & control , Amniotic Fluid , Animals , Female , Gastric Mucosa/metabolism , Guinea Pigs , Humans , Infant, Newborn , Injections , Lung/diagnostic imaging , Lung/metabolism , Models, Animal , Placenta/diagnostic imaging , Placenta/drug effects , Placenta/metabolism , Pregnancy , Pulmonary Surfactants/administration & dosage , Radionuclide Imaging , Stomach/diagnostic imaging , Stomach/drug effectsABSTRACT
OBJECTIVE: There are no randomized studies of the two therapeutic alternatives (surgery or radiotherapy) for occult cervical carcinoma, and survival rates in the absence of residual cancer seem to be similar for both. This article presents our experience with radical reoperation for occult cervical carcinoma. MATERIALS AND METHODS: Eleven patients with occult cervical cancer, primary invasive tumor >/=0.5 cm and
ABSTRACT
En algunas oportunidades, el estudio del útero extirpado por patología benigna, revela sorpresivamente la presencia de un cáncer cervical invasor. No existen estudios randomizados que comparen las dos modalidades terapéuticas para esta situación (cirugía o radioterápia), y las tasas de sobrevida en ausencia de tumor residual aparenta ser similar con cualquiera de las dos opciones. Presentamos nuestra experiencia con la reoperación radical para el tratamiento del carcinoma oculto del cuello uterino
Subject(s)
Female , Carcinoma , Cervix Uteri , Hysterectomy, VaginalABSTRACT
OBJECTIVE: This study compared the rates of survival, recurrence, and the occurrence of complications after surgery for vulvar cancer in selected patients treated by simple vulvectomy or wide local excision (WLE) and ipsilateral superficial inguinal lymphadenectomies (ISIL) and who were in a representative group of previous patients treated by standard radical surgery (control). MATERIALS AND METHODS: Superficial inguinal lymphadenectomies were performed in 32 patients with laterally localized squamous cell tumors of 1 to 3 cm in size and without palpable lymph nodes. Eight cases, which showed histological evidence of lymph node metastasis, were submitted to conventional radical treatment and excluded from the study. Of the remaining 24 patients, 12 underwent vulvectomy, 7 hemivulvectomy, and 5 WLE. The results of this group were compared with those of 21 historical controls who previously had tumors of 1 to 3 cm and had been treated by radical vulvectomy with superficial and deep bilateral inguinal lymphadenectomy. RESULTS: Dehiscence of the flaps occurred in 66.6% of the control patients and in 8.3% of the ISIL group (chi , p <.0001). There was lymphedema in 13.8% of the controls and none in the ISIL group (Fisher exact test, p <.02). Upon follow-up (3 to 8 years, results are reported for 3 years of follow-up), there were 9.5% vulvar recurrences in the controls and 12.5% in the ISIL group (Fisher exact test, p <.652 not significant). CONCLUSIONS: WLE and deep local excision of the primary lesion and ISIL in selected patients with early vulvar cancer seems to be a safe alternative to the traditional radical method.
